News

A newly authorized phase 1b study will evaluate the safety and efficacy of the continuous delivery of lenalidomide among patients with multiple myeloma.

According to phase 2 study results, the combination of prolgolimab, bevacizumab and platinum doublet chemotherapy showed promising efficacy and an adequate safety profile in cervical cancer.

Though scientific advances have been encouraging in the thyroid cancer space, there is much more work to be done to figure out exactly how to tailor the right therapy, or combination of therapies, for individual patients.

The phase 2a portion of a study will evaluate fostrox as a triplet in earlier lines of immunotherapy combinations for patients with hepatocellular carcinoma.

The FDA has requested additional time to assess the analyses of previously submitted data from the phase 3 DeFi trial of nirogacestat in desmoid tumors, leading to an extension of the Prescription Drug User Fee Act decision date.

In part C of the phase 2 SGN35-027 trial evaluating brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine in patients with classical Hodgkin lymphoma, fewer than half of patients developed primarily low-grade peripheral neuropathy, and no cases of febrile neutropenia were observed.

Bhagirathbhai R. Dholaria, MBBS, discusses updated findings from the TRIMM-2 trial of talquetamab and daratumumab for the treatment of relapsed/refractory multiple myeloma.

Promising data were revealed with nelarabine, intensive L-asparaginase, and protracted intrathecal therapy among patients aged 25 years and younger with T-cell acute lymphoblastic leukemia.

The use of polatuzumab vedotin in place of vincristine in R-mini-CHOP may lead to an increase in gastrointestinal adverse events in frail patients with diffuse large B-cell lymphoma.

Data from the phase 3 CAPItello-291 trial of capivasertib plus fulvestrant in HR-positive, HER2-negative locally advanced or metastatic breast cancer have led the FDA to grant priority review to the new drug application for the combination.

Yael Cohen, MD, discusses the main safety findings from the phase 1/2 RedirecTT-1 trial, which is evaluating the combination of teclistamab-cqyv and talquetamab for the treatment of patients with relapsed/refractory multiple myeloma.

In patients with FLT3-ITD–mutant acute myeloid leukemia and detectable minimal residual disease after hematopoietic stem cell transplant, treatment with gilteritinib elicited a 48% reduction vs patients without detectable MRD.

In an interview with Targeted Oncology, Jonathan C. Trent, MD, PhD, discussed primary and offshoot analysis data from the INTRIGUE study of patients with GIST.

Findings from the phase 3 PhALLCON trial show that ponatinib plus reduced-intensity chemotherapy could be a new standard of care for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

The Association for Clinical Oncology has provided recommendations to the FDA for its draft guidance, which reflects a strong preference for randomized controlled trials.

Preliminary findings from arm 4 of the phase 2 MANIFEST trial show hematologic response and symptom improvement with pelabresib in high-risk essential thrombocythemia that is refractory or intolerant to hydroxyurea.

Treatment with maintenance daratumumab, with or without pomalidomide, led to a median PFS of 28.5 months in patients with relapsed multiple myeloma after undergoing salvage autologous hematopoietic stem cell transplantation.

Patients aged 80 years or older and/or considered frail who received acalabrutinib for chronic lymphocytic leukemia experienced toxicities consistent with prior trials.

In patients with relapsed/refractory multiple myeloma who were previously treated with lenalidomide, the combination of daratumumab, ixazomib, and dexamethasone led to improved overall response rates.

The addition of acalabrutinib to bendamustine and rituximab met tolerability and safety end points in a phase 1b trial, as well as promising efficacy results in patients with either treatment-naive or relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, discusses what led to the start of the phase 3 BRUIN MCL-321 trial for patients with mantle cell lymphoma.

A regular review of an FDA approval application is underway for the combination of pembrolizumab and standard chemotherapy for the treatment of advanced biliary tract cancer.

The FoundationOne®Liquid CDx has received FDA approval as a companion diagnostic for encorafenib plus cetuximab for patients with BRAF V600E-mutated metastatic colorectal cancer.

Results presented in a poster at the 2023 ASCO Annual Meeting demonstrated similar progression-free survival between acalabrutinib and zanubrutinib in patients with chronic lymphocytic leukemia.

Experts say results from a phase 1 study of olverembatinib in patients with succinate dehydrogenase-deficient gastrointestinal stromal tumor were encouraging and warrant further research.

Hope S. Rugo, MD, FASCO, discusses background and key findings from the phase 3 CAPItello-291 trial in breast cancer.

Treatment with INT230-6 alone led to extended survival among patients with soft tissue sarcoma by nearly 450 days, compared with synthetic controls, and demonstrated a favorable safety profile.

Now that the FDA has lifted the partial clinical hold on the phase 1 study of FHD-286 in patients with relapsed/refractory acute myelogenous leukemia and myelodysplastic syndrome, there are plans to initiate a trial to further assess the agent with decitabine or cytarabine.

In an interview with Targeted Oncology, Alexander Helfand, MD discussed the current standard practice for testing patients with renal cell carcinoma and administering immunotherapy or targeted therapy.

Updated progression-free survival analysis data presented at the 2023 ASCO Annual Meeting favored the combination of nivolumab plus relatlimab in patients with melanoma.